Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steinebach

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Chemical Communications (Cambridge, England)|July 19, 2022
Targeting the deubiquitinase USP7 for degradation with PROTACsArunima Murgai, Izidor Sosič, Martina Gobec, et al.
ACS Chemical Biology|August 18, 2018
Homo-PROTACs for the Chemical Knockdown of CereblonChristian Steinebach, Stefanie Lindner, Namrata D Udeshi, et al.
Archiv Der Pharmazie|February 7, 2022
Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer modelsLukas M Gockel, Vladlena Pfeifer, Fabian Baltes, et al.
Biochemical and Biophysical Research Communications|December 14, 2020
On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugsChristopher Heim, Samuel Maiwald, Christian Steinebach, et al.
Medchemcomm|July 16, 2019
A MedChem toolbox for cereblon-directed PROTACsChristian Steinebach, Izidor Sosič, Stefanie Lindner, et al.
Der Anaesthesist|November 11, 2011
[Update: studies in intensive care medicine. Results of the last 12 months]J Knapp, G Marx, K Weismüller, et al.
RSC Medicinal Chemistry|July 11, 2022
Encoding BRAF inhibitor functions in protein degradersDaniel S J Miller, Sabine A Voell, Izidor Sosič, et al.
Chemical Communications (Cambridge, England)|September 13, 2022
Development of the first non-hydroxamate selective HDAC6 degradersTim Keuler, Beate König, Nico Bückreiß, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2024
Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivativesJohannes Sievers, Rabea Voget, Feiteng Lu, et al.
Neurogastroenterology and Motility|May 2, 2015
The novel CGRP receptor antagonist BIBN4096BS alleviates a postoperative intestinal inflammation and prevents postoperative ileusT R Glowka, A Steinebach, K Stein, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Chemical Communications (Cambridge, England)|July 19, 2022
Targeting the deubiquitinase USP7 for degradation with PROTACsArunima Murgai, Izidor Sosič, Martina Gobec, et al.
ACS Chemical Biology|August 18, 2018
Homo-PROTACs for the Chemical Knockdown of CereblonChristian Steinebach, Stefanie Lindner, Namrata D Udeshi, et al.
Archiv Der Pharmazie|February 7, 2022
Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer modelsLukas M Gockel, Vladlena Pfeifer, Fabian Baltes, et al.
Biochemical and Biophysical Research Communications|December 14, 2020
On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugsChristopher Heim, Samuel Maiwald, Christian Steinebach, et al.
Medchemcomm|July 16, 2019
A MedChem toolbox for cereblon-directed PROTACsChristian Steinebach, Izidor Sosič, Stefanie Lindner, et al.
Der Anaesthesist|November 11, 2011
[Update: studies in intensive care medicine. Results of the last 12 months]J Knapp, G Marx, K Weismüller, et al.
RSC Medicinal Chemistry|July 11, 2022
Encoding BRAF inhibitor functions in protein degradersDaniel S J Miller, Sabine A Voell, Izidor Sosič, et al.
Chemical Communications (Cambridge, England)|September 13, 2022
Development of the first non-hydroxamate selective HDAC6 degradersTim Keuler, Beate König, Nico Bückreiß, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2024
Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivativesJohannes Sievers, Rabea Voget, Feiteng Lu, et al.
Neurogastroenterology and Motility|May 2, 2015
The novel CGRP receptor antagonist BIBN4096BS alleviates a postoperative intestinal inflammation and prevents postoperative ileusT R Glowka, A Steinebach, K Stein, et al.
Pageof 11